Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK

But Experts Doubt It Can Overtake J&J’s Entrenched Darzalex

 
• By Sten Stovall
  
Silver medal
Sarclisa is second anti-CD38 to reach market after Darzalex • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip